Arbutus Biopharma Corp
ABUS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001447028
No open-market purchases or sales by Arbutus Biopharma Corp insiders were filed in the last 90 days; 176 institutions reported holding it in 13F filings for Q2 2026, worth $674.9M in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Arbutus Biopharma Corp as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 100
- +10 vs. Q2 2021
- Shares held
- 34.9M
- +5.99M (+20.7%) vs. Q2 2021
- Total value
- $149.8M
- +$62.1M (+70.9%) vs. Q2 2021
- New holders
- 24
- 31 more added
- Sold out
- 14
- 23 more reduced
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ABUS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 176 | $674.9M |
| Q1 2026 | 167 | $625.4M |
| Q4 2025 | 172 | $586.9M |
| Q3 2025 | 166 | $536.4M |
| Q2 2025 | 163 | $365.0M |
| Q1 2025 | 168 | $390.1M |
| Q4 2024 | 154 | $340.3M |
| Q3 2024 | 144 | $389.2M |
| Q2 2024 | 131 | $298.4M |
| Q1 2024 | 119 | $215.2M |
| Q4 2023 | 112 | $197.4M |
| Q3 2023 | 99 | $143.8M |
| Q2 2023 | 111 | $152.4M |
| Q1 2023 | 122 | $189.3M |
| Q4 2022 | 114 | $126.3M |
| Q3 2022 | 127 | $89.1M |
| Q2 2022 | 113 | $120.0M |
| Q1 2022 | 119 | $130.6M |
| Q4 2021 | 123 | $154.4M |
| Q3 2021 | 100 | $149.8M |
| Q2 2021 | 91 | $87.6M |
| Q1 2021 | 94 | $86.5M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Arbutus Biopharma Corp; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −119,020−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −93,196−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −86,771−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −62,310−100.0% | Sold out |
| AQR Capital Management LLC | 0 | $0 | 0.00% | −19,036−100.0% | Sold out |
| Assenagon Asset Management S.A. | 0 | $0 | 0.00% | −17,851−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −15,474−100.0% | Sold out |
| IHT Wealth Management, LLC | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| Bay Colony Advisory Group, Inc d/b/a Bay Colony Advisors | 0 | $0 | 0.00% | −13,000−100.0% | Sold out |
| Sargent Investment Group, LLC | 0 | $0 | 0.00% | −12,339−100.0% | Sold out |
| Scotia Capital Inc. | 0 | $0 | 0.00% | −11,690−100.0% | Sold out |
| Retirement Group, LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| AdvisorNet Financial, Inc | 0 | $0 | 0.00% | −272−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| CWM, LLC | – | – | – | – | Not filed |